LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on spinocerebellar ataxia. The report includes a detailed analysis of the pipeline molecules under ...

A team has conducted a trial on the efficacy and safety of L-arginine in treating spinocerebellar ataxia type 6 (SCA6). The findings are published in the journal eClinicalMedicine, and the team was ...

Spinocerebellar ataxia (SCA) is a degenerative disease caused by atrophy to the cerebellum, the part of the brain responsible for coordination of movement. Clinical features of spinocerebellar ataxia ...

The first in vivo trial of the use of interferon-beta in a mouse model of the group of fatal diseases known as spinocerebellar ataxia has shown that its use can significantly improve their physical ...

A European research alliance tracks the onset of ataxias "Spinocerebellar ataxias" are diseases of the nervous system associated with a loss of motor coordination. A European research alliance headed ...

(RTTNews) - Biohaven Ltd. (BHVN) announced that the Division of Neurology 1 within FDA's Office of Neuroscience informed the company that they have extended the PDUFA date for the troriluzole new drug ...

Please provide your email address to receive an email when new articles are posted on . DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Riluzole did not improve clinical or radiological ...

If approved, troriluzole would be the first and only FDA-approved treatment for SCA. Spinocerebellar ataxia is a group of dominantly inherited neurodegenerative disorders characterized by progressive ...

(BPT) – A rare disease is a disease, disorder, illness or condition that affects fewer than 200,000 Americans. 1 Since rare diseases impact a small number of people, they often remain relatively ...